Advertisement: Bicycle mid banner
Advertisement: CambridgeTechPodcast midbanner
Advertisement: Featurespace mid banner
Advertisement mid banner S-Tech 3
Advertisement: Cambridge Network mid banner
Advertisement: Alan Boswell Group mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: SATAVIA mid banner
Advertisement: Mogrify mid banner
Advertisement: SourceBioscience mid banner
Advertisement: Wild Knight Vodka
Advertisement: TTP
Cambridgeand mid banner advertisement
Advertisement: Birketts mid banner
Advertisement: Shearline mid banner
Advertisement: Arm mid banner
Advertisement: cofinitive mid banner
Advertisement: RSM mid banner
Advertisement: Marshall mid banner
Advertisement: Ilux mid banner
Advertisement: Evelyn mid banner
Advertisement: Simpsons Creative mid banner
Advertisement: Allia mid banner
Advertisement: CJBS mid banner
Advertisement: SJIP Dirac Building mid-banner
Mid banner advertisement: BDO
Barr Ellison Solicitors – commercial property
10 August, 2012 - 14:43 By News Desk

FDA uses Linguamatics to boost drug safety

John Brimacombe

Linguamatics, a Cambridge UK company specialising in text mining technology, has secured a remarkable coup with the Food and Drug Administration.

The FDA’s Center for Drug Evaluation and Research has licensed the company’s I2E text mining platform to support laboratory research efforts on drug safety. Financial details of the agreement were not disclosed.

Linguamatics says the deal reflects the continued growth in demand for NLP-based text mining as a key knowledge discovery and decision support tool in the pharmaceutical, biotechnology and healthcare sectors.

During the term of the licence, the centre will use I2E to mine published literature and drug product labels to answer questions relating to a range of biomedical topics, including drug toxicity mechanisms and disease processes.

Linguamatics says that I2E’s NLP-based querying capabilities, coupled with its scalability and flexibility, mean it is ideally suited to answering many challenging, high value questions in life sciences and healthcare by unlocking knowledge buried in the scientific literature and other textual information.

Rather than just retrieving documents, I2E can rapidly identify, extract, synthesize and analyse specific, relevant facts and relationships, such as those between genes and diseases or compounds and side effects. Customers include nine of the top 10 global pharmaceutical companies.

John Brimacombe, executive chairman at Linguamatics, said: “We are very pleased to welcome CDER/FDA as a customer. Their adoption of the I2E text mining platform reflects the continued growth in demand for NLP-based text mining as a key knowledge discovery and decision support tool in the pharmaceutical, biotechnology and healthcare sectors.”

The FDA is an agency within the U.S. Department of Health and Human Services.

• PHOTOGRAPH SHOWS: John Brimacombe

Add new comment

Newsletter Subscription

Stay informed of the latest news and features